制造商: 阿基米德制药 类药物: 活性成分(S): 指示(S): 药理: 临床试验: 法律分类: 成人: 儿童: 禁忌(S):
相互作用(S): 不良反应(S): 注: 如何提供:
日前,第一个也是唯一的芬太尼鼻腔喷雾剂(Lazanda,Archimedes)在美国通过FDA审批。这个新药用于控制成人癌症暴发痛,从而解决阿片疗法耐受的问题。而在欧洲,这种药物商品名为PecFent(芬太尼果胶喷鼻剂),已在5个国家开始销售。 芬太尼被批准可用于成人癌性爆发痛 10月20日消息:芬太尼鼻腔喷雾剂目前已在5 个欧洲国家上市。Lazanda 使用了获得专利的PecSys 药物传递系统,通过一种快速且控释的方式给药,是经历极度爆发性癌痛患者的重要新选择。据介绍,美国FDA 批准芬太尼鼻腔喷雾剂(Lazanda)治疗成人癌症患者的爆发性疼痛,其应用指征为不少于18 周岁、已接受阿片类药物治疗但对治疗方案已耐药的患者。 芬太尼的适应证仅为对阿片类药物耐药的爆发性疼痛患者,禁忌于阿片类药物不耐受患者的疼痛治疗,因为在阿片类药物不间断治疗的患者中应用任何剂量该药都可能发生通气不足而威胁生命。此外,该剂型药物也不能与其他治疗爆发性疼痛的芬太尼产品等换,因它们的药物动力学特性并不同,可能导致致命剂量的出现。特殊人群的使用18 岁以下患者应用该药的安全性和有效性证据尚不足。只有当明确该药对胎儿的潜在益处大于潜在风险时方能用于孕妇,而接受一般镇痛及分娩镇痛治疗的女性暂不推荐使用该药。肝肾功能不良的患者慎用该药,存在严重肝肾疾病的患者应逐步滴定给药。 Manufacturer:Archimedes Pharma Pharmacological Class:Opioid. Active Ingredient(s):Fentanyl 100mcg, 400mcg; per 100mcL nasal spray. Indication(s):Breakthrough pain, in opioid-tolerant patients already receiving and who are tolerant to continuous opioid therapy for underlying persistent cancer pain. Opioid-tolerant patients are those taking oral morphine ≥60mg/day, transdermal fentanyl ≥25mcg/hr, oral oxycodone ≥30mg/day, oral hydromorphone ≥8mg/day, oral oxymorphone ≥25mg/day, or equianalgesic dose of another opioid for ≥1 week. Pharmacology:Like other pure opioid agonists, fentanyl acts on the mu-receptors in the CNS to produce analgesia and CNS depression. Clinical Trials:The efficacy of Lazanda was evaluated in one clinical trial in opioid tolerant adult patients experiencing breakthrough cancer pain. The clinical trial included an open-label titration phase where a dose was identified that provided adequate analgesia with tolerable side effects, within the range of 100 to 800mcg. In the double-blind, placebo-controlled portion of the study, patients who were titrated to an adequate dose were randomized to a blinded sequence of 10 treatments with 7 being the identified dose of Lazanda and 3 being placebo. The primary outcome measure, the mean sum of the pain intensity difference at 30 minutes, was statistically significantly higher for Lazanda than for placebo. Legal Classification:CII Adults:≥18years: Prime device before use. Initially one 100mcg spray in one nostril; if adequate analgesia obtained within 30 minutes, treat subsequent episodes with this dose. If adequate analgesia not achieved, dose escalate in a step-wise manner over consecutive episodes until adequate analgesia achieved; wait at least 2 hours before using for the next episode. Titration steps: 100mcg using 1 x 100mcg spray; 200mcg using 2 x 100mcg spray (1 in each nostril); 400mcg using 1 x 400mcg; 800mcg using 2 x 400mcg (1 in each nostril); max 800mcg. Maintenance: once an appropriate dose has been established, use that dose for subsequent breakthrough episodes. Limit to ≤4 doses per day. May use rescue medication if there is inadequate pain relief after 30 minutes of Lazanda dosing or if a separate episode occurs before the next dose of Lazanda is permitted (ie, within 2 hours). Children:<18years: not recommended. Contraindication(s):Opioid non-tolerant patients. Acute or post-op pain (including headache/migraine, dental pain, or ER). Warnings/Precautions:Do not substitute with other fentanyl products; not equivalent to other fentanyl products on a mcg to mcg basis. Respiratory disorders or depression. Head injury. Increased intracranial pressure. Bradyarrhythmias. Impaired pulmonary, cardio, renal, or hepatic function. Elderly. Debilitated. Pregnancy (Cat. C). Labor & delivery, nursing mothers: not recommended. Interaction(s):Not recommended within 14 days of MAOIs. Potentiates CNS depression with alcohol, other CNS depressants (eg, phenothiazines, skeletal muscle relaxants, antihistamines, hypnotics). Potentiated by CYP3A4 inhibitors (eg, macrolides, azole antifungals, aprepitant, protease inhibitors, nefazodone, verapamil, diltiazem). Antagonized by CYP3A4 inducers (eg, barbiturates, efavirenz, modafinil, nevirapine, anticonvulsants, pioglitazone, troglitazone, rifabutin, rifampin, St John’s wort). Efficacy may be lowered with concomitant vasoconstrictive nasal agents use to treat allergic rhinitis. Adverse Reaction(s):GI upset, constipation, dizziness, pyrexia. Notes:Available by restricted distribution program. Call (855) 841-4234 or visit www.LazandaREMS.com to enroll. How Supplied:Nasal spray (8 sprays/bottle)—1 |
芬太尼鼻腔喷雾剂PecFent(Lazanda,Archimedes)简介:
制造商:阿基米德制药
类药物:阿片类药物。
活性成分(S):芬太尼100mcg,400mcg;每100mcL喷鼻剂。
指示(S):突破性疼痛,阿片类药物耐受的患者已经接受和耐受连续底层的持久癌症疼痛的阿片类药物 ... 责任编辑:admin |
最新文章更多
推荐文章更多
热点文章更多 |